Structure Therapeutics Inc. (GPCR)
Fuera de horario:
Structure Therapeutics Inc.
601 Gateway Boulevard
Suite 900
South San Francisco, CA 94080
United States
(650) 457-1978
https://structuretx.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 111
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. Raymond C. Stevens Ph.D. | CEO & Director | 890.38k | N/D | 1964 |
| Mr. Jun S. Yoon | Co- Founder, CFO & Secretary | 627.64k | N/D | 1978 |
| Dr. Mark A. Bach M.D., Ph.D. | Chief Medical Officer | 672.06k | N/D | 1957 |
| Dr. Yingli Ma Ph.D. | Chief Technology Officer | 497.58k | N/D | 1974 |
| Dr. Xichen Lin Ph.D. | Chief Scientific Officer | N/D | N/D | 1974 |
| Mr. Tony Peng | Senior Vice President of Legal | N/D | N/D | N/D |
| Mr. Bob Gatmaitan | Senior Vice President of People | N/D | N/D | N/D |
| Dr. Hui Lei Ph.D. | Senior Vice President of Chemistry | N/D | N/D | N/D |
| Dr. Fang Zhang Ph.D. | Executive VP & Head of Biology | N/D | N/D | N/D |
| Ms. Lani Ibarra | Senior Vice President of Clinical Development Operations | N/D | N/D | N/D |
Descripción
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF); and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF and PPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
Gestión corporativa
La calificación ISS Governance QuickScore de Structure Therapeutics Inc. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.
